RCT | Sotorasib vs. docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

Docetaxel is the recommended treatment for non-small-cell lung cancer (NSCLC) at disease progression, but it has shown modest clinical benefit.

The CodeBreaK 200 trial compares the KRAS inhibitor sotorasib with docetaxel in patients with advanced NSCLC.https://t.co/Sk7Rk1lAl2

— The Lancet (@TheLancet) March 9, 2023